Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.63 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124085 | 0.90 | MAPT (0.81) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4106278 | 0.88 | TRPV1 (0.74) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4111778 | 0.88 | TRPV1 (0.74) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4118207 | 0.88 | TRPV1 (0.74) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1019967 | 0.87 | SMN1; SMN2 (0.78) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4118384 | 0.86 | MAPT (0.76) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4920497 | 0.86 | MAPT (0.75) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14468114 | 0.86 | TRPV1 (0.73) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4104609 | 0.86 | TRPV1 (1.00) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4113506 | 0.86 | RAB9A (0.79) | TRPV1MAPTSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215705-A1 | hTRPV1 CHEMICAL AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-08-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | TRPV1 3771/4885MAPT 4416/4885SMN1; SMN2 4525/4885 |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | TRPV1 169/4885MAPT 1654/4885SMN1; SMN2 4056/4885 |
| US-20180215705-A1 | hTRPV1 CHEMICAL AGENTS | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885MAPT 4496/4885SMN1; SMN2 2497/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | TRPV1 1369/4885MAPT 4477/4885SMN1; SMN2 3609/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | TRPV1 1369/4885MAPT 4477/4885SMN1; SMN2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.